1. Home
  2. PBT vs ANNX Comparison

PBT vs ANNX Comparison

Compare PBT & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Permian Basin Royalty Trust

PBT

Permian Basin Royalty Trust

HOLD

Current Price

$30.02

Market Cap

1.0B

Sector

Energy

ML Signal

HOLD

Logo Annexon Inc.

ANNX

Annexon Inc.

HOLD

Current Price

$5.41

Market Cap

812.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PBT
ANNX
Founded
1980
2011
Country
United States
United States
Employees
N/A
93
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
812.7M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
PBT
ANNX
Price
$30.02
$5.41
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$16.50
AVG Volume (30 Days)
201.0K
1.9M
Earning Date
03-13-2026
05-11-2026
Dividend Yield
1.50%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$16,320.74
P/E Ratio
$57.37
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.80
$1.85
52 Week High
$31.85
$7.18

Technical Indicators

Market Signals
Indicator
PBT
ANNX
Relative Strength Index (RSI) 72.66 44.32
Support Level $16.88 $5.28
Resistance Level N/A $5.61
Average True Range (ATR) 1.90 0.29
MACD 0.58 -0.06
Stochastic Oscillator 78.11 41.18

Price Performance

Historical Comparison
PBT
ANNX

About PBT Permian Basin Royalty Trust

Permian Basin Royalty Trust is an express trust. The company's underlying properties include Waddell Ranch Properties in which the trust holds mineral interest as well as royalty interests in mature producing oil fields, such as Yates, Wasson, Sand Hills, East Texas, Kelly-Snyder, Panhandle Regular, N. Cowden, Todd, Keystone, Kermit, McElroy, Howard-Glasscock, Seminole, and others across Texas. The company earns the majority of its revenue in the form of royalties received through its properties.

About ANNX Annexon Inc.

Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.

Share on Social Networks: